ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 300 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,817 | -13.0% | 10,020 | 0.0% | 0.16% | -6.4% |
| Q2 2023 | $239,979 | +24.2% | 10,020 | -2.4% | 0.17% | +19.3% |
| Q1 2023 | $193,281 | +18.2% | 10,270 | 0.0% | 0.14% | +8.2% |
| Q4 2022 | $163,498 | -2.7% | 10,270 | 0.0% | 0.13% | -10.7% |
| Q3 2022 | $168,000 | +15.9% | 10,270 | 0.0% | 0.15% | +25.0% |
| Q2 2022 | $145,000 | -41.5% | 10,270 | +0.5% | 0.12% | -31.0% |
| Q1 2022 | $248,000 | +3.8% | 10,220 | 0.0% | 0.17% | +9.4% |
| Q4 2021 | $239,000 | -1.2% | 10,220 | +125.9% | 0.16% | -18.5% |
| Q4 2020 | $242,000 | +10.5% | 4,525 | 0.0% | 0.20% | -10.1% |
| Q2 2020 | $219,000 | +8.4% | 4,525 | -5.2% | 0.22% | -12.1% |
| Q1 2020 | $202,000 | -22.9% | 4,775 | -22.1% | 0.25% | +2.9% |
| Q4 2019 | $262,000 | +18.6% | 6,127 | 0.0% | 0.24% | +9.6% |
| Q3 2019 | $221,000 | – | 6,127 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |